Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to “Hold” at Wall Street Zen

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a report released on Saturday.

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.83.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $19.86 on Friday. Catalyst Pharmaceuticals has a one year low of $17.58 and a one year high of $26.58. The stock’s fifty day moving average price is $22.26 and its two-hundred day moving average price is $22.79. The firm has a market cap of $2.42 billion, a PE ratio of 12.04, a price-to-earnings-growth ratio of 0.80 and a beta of 0.70.

Insiders Place Their Bets

In related news, insider Gary Ingenito sold 44,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider owned 68,873 shares in the company, valued at $1,627,468.99. The trade was a 38.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the business’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider owned 41,081 shares in the company, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 247,924 shares of company stock worth $5,879,369 in the last 90 days. 10.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. LPL Financial LLC lifted its stake in shares of Catalyst Pharmaceuticals by 38.0% in the 4th quarter. LPL Financial LLC now owns 57,983 shares of the biopharmaceutical company’s stock valued at $1,210,000 after purchasing an additional 15,961 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Catalyst Pharmaceuticals by 80.3% in the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock valued at $15,364,000 after purchasing an additional 327,936 shares during the period. Norges Bank acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $1,915,000. Envestnet Asset Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 162.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 64,395 shares of the biopharmaceutical company’s stock valued at $1,344,000 after purchasing an additional 39,836 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Catalyst Pharmaceuticals by 1.4% in the 4th quarter. Russell Investments Group Ltd. now owns 176,259 shares of the biopharmaceutical company’s stock valued at $3,679,000 after purchasing an additional 2,471 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.